Drugs / AP306
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06712654 | Jun 2026 → Feb 2027 expected | end stage renal failure, hyperphosphatemia | R1 Therapeutics | Recruiting | No outcome recorded |
| Phase 2 | NCT05764590 | Feb → Aug 2023 | chronic kidney disease, hyperphosphatemia | Alebund Pharmaceuticals | Completed | Met primary |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2024-06-25 | Alebund Pharmaceuticals | Regulatory 礼邦医药在研创新药物 AP306 获国家药品监督管理局突破性治疗药物认定用于治疗慢性肾脏病高磷血症 alebund.com ↗
公司宣布其在研创新药物 AP306 获国家药品监督管理局药品审评中心突破性治疗药物认定用于治疗慢性肾脏病高磷血症。 |
| 2024-05-27 | Alebund Pharmaceuticals | Results 礼邦医药在第 61 届欧洲肾脏协会（ERA）年会上公布其 AP306 Ⅱ期临床试验数据 alebund.com ↗
在已完成的Ⅱ期临床研究（NCT05764590）中，AP306 单药治疗显著降低血液透析合并高磷血症患者的血清磷，并大幅提高血清磷控制率。 |
| 2023-12-15 | Alebund Pharmaceuticals | Results 礼邦医药宣布首款钠依赖性磷酸盐转运蛋白泛抑制剂 AP306（EOS789）完成在透析合并高磷血症患者中的 2 期临床试验 alebund.com ↗
治疗结束时，AP306 组血清磷较基线降低幅度具有临床意义；AP306 治疗组应答率（定义为血清磷低于 5.5 mg/dL）明显高于碳酸司维拉姆治疗组。 |
All press releases naming this drug 7 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-07-21 | R1 Therapeutics | R1 Therapeutics announces commencement of global Phase 2b trial of AP306 for hyperphosphatemia in patients on dialysis r1therapeutics.com ↗ |
| 2026-07-21 | Alebund Pharmaceuticals | 礼邦医药宣布 AP306 全球多区域IIb 期临床试验完成首例受试者随机入组并给药 alebund.com ↗ |
| 2026-06-30 | R1 Therapeutics | R1 Therapeutics establishes world-class Scientific Advisory Board to support advancement of AP306 in Chronic Kidney Disease r1therapeutics.com ↗ |
| 2026-03-17 | Alebund Pharmaceuticals | 礼邦医药宣布与 R1 Therapeutics 达成 AP306 股权及海外授权合作协议 alebund.com ↗ |
| 2024-06-25 | Alebund Pharmaceuticals | 礼邦医药在研创新药物 AP306 获国家药品监督管理局突破性治疗药物认定用于治疗慢性肾脏病高磷血症 alebund.com ↗ |
| 2024-05-27 | Alebund Pharmaceuticals | 礼邦医药在第 61 届欧洲肾脏协会（ERA）年会上公布其 AP306 Ⅱ期临床试验数据 alebund.com ↗ |
| 2023-12-15 | Alebund Pharmaceuticals | 礼邦医药宣布首款钠依赖性磷酸盐转运蛋白泛抑制剂 AP306（EOS789）完成在透析合并高磷血症患者中的 2 期临床试验 alebund.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AP-306 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05764590 ↗ |
| Action | Inhibit | “AP306 is a pan-phosphate transporter inhibitor” NCT06712654 ↗ |
| Route | Oral | “AP306 75 mg by mouth, twice daily (150 mg/day).” NCT06712654 ↗ |